Center for Minimally Invasive Gynecologic Surgery, Newton Wellesley Hospital, Newton, MA.
About Women By Women Obstetrics and Gynecology, Wellesley, MA.
JSLS. 2022 Jul-Sep;26(3). doi: 10.4293/JSLS.2022.00028.
To identify intraoperative factors during laparoscopic hysterectomy associated with postoperative opioid use and increased pain scores during the acute postoperative period.
This is a prospective survey-based cohort study at two teaching hospitals in the Boston metropolitan area. A total of 125 patients undergoing laparoscopic hysterectomy were enrolled. Surveys were administered by telephone at one-week postoperatively and in-person at their two-week postoperative visit to elicit opioid consumption converted to morphine milligram equivalents (MMEs) and pain scores.
The median total opioid consumption was 37.5 MME (range 0-960 MMEs). Intraoperative factors associated with increased total MME consumption were lower uterine weight and resection of endometriosis at the time of surgery. Patients with uteri less than 250 grams used twice as much opioid compared to participants with uteri greater than 250 grams (median of 49.8 MME (interquartile range [IQR] 7.5-120.5) vs. 22.5 MME (IQR 7.5-61.0). The median opioid consumption by patients with resection or ablation of endometriosis was three times that of those who did not undergo surgical treatment of endometriosis (97.0 MME (IQR 53.1-281.3) vs. 30.0 MMEs (IQR 7.5-81.3 MME)). Maximum pain scores and reported pain score at one and two-week interviews were also significantly higher in patients with these characteristics.
Several easily identified intraoperative factors may be correlated with opioid requirements during the acute postoperative period. This can allow surgeons to set expectations and dispense patient-specific opioid prescriptions. Individualizing prescriptions may lower the amount of excess circulating opioids and help combat the opioid epidemic.
明确腹腔镜子宫切除术术中的相关因素与术后急性疼痛期内阿片类药物使用及疼痛评分增加的相关性。
这是在波士顿大都市区的两家教学医院进行的前瞻性基于调查的队列研究。共纳入 125 例行腹腔镜子宫切除术的患者。术后一周通过电话、术后两周门诊访视时通过问卷调查的方式收集患者阿片类药物使用情况(换算为吗啡毫克当量)和疼痛评分。
中位总阿片类药物消耗量为 37.5 吗啡毫克当量(范围 0-960 吗啡毫克当量)。术中与总吗啡毫克当量消耗增加相关的因素包括子宫重量较低以及手术时切除子宫内膜异位症。子宫重量小于 250 克的患者比子宫重量大于 250 克的患者使用的阿片类药物多一倍(中位数为 49.8 吗啡毫克当量(四分位距 [IQR] 7.5-120.5)比 22.5 吗啡毫克当量(IQR 7.5-61.0)。行子宫内膜异位症切除术或消融术的患者的阿片类药物消耗量中位数是未行子宫内膜异位症手术治疗的患者的三倍(97.0 吗啡毫克当量(IQR 53.1-281.3)比 30.0 吗啡毫克当量(IQR 7.5-81.3)。有这些特征的患者的最大疼痛评分和术后 1 周和 2 周时报告的疼痛评分也明显更高。
一些术中容易识别的因素可能与术后急性疼痛期内的阿片类药物需求相关。这可以使外科医生设定预期并开出特定于患者的阿片类药物处方。个体化处方可能会减少循环阿片类药物的过量,并有助于对抗阿片类药物流行。